

**Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

Antiviral Drugs Advisory Committee

May 19, 2005

*Hilton
620 Perry Parkway
Gaithersburg, Maryland*

DRAFT AGENDA

The Antiviral Drugs Advisory Committee will discuss new drug application (NDA) 021-814, proposed tradename Aptivus (Tipranavir) 250 milligrams (mg) capsules, Boehringer Ingelheim Pharmaceuticals, Inc., indicated for the treatment of patients with HIV.

8:00 Call to Order and Opening Remarks

Introduction of Committee

Conflict of Interest Statement

Anuja Patel, M.P.H.
Executive Secretary, FDA

Overview of Issues

Sponsor Presentations

FDA Presentations

Lunch

Open Public Hearing

Discussion and Questions to the Committee

5:00 Adjourn